Analysts forecast that Nyxoah S.A. (NASDAQ:NYXH – Get Rating) will announce sales of $480,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Nyxoah’s earnings, with estimates ranging from $420,000.00 to $530,000.00. Nyxoah reported sales of $220,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 118.2%. The firm is scheduled to issue its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Nyxoah will report full-year sales of $5.46 million for the current fiscal year, with estimates ranging from $5.41 million to $5.51 million. For the next financial year, analysts forecast that the company will report sales of $13.72 million, with estimates ranging from $13.43 million to $14.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Nyxoah.
Several research analysts recently weighed in on NYXH shares. Zacks Investment Research downgraded Nyxoah from a “buy” rating to a “hold” rating in a research note on Friday, April 1st. Wolfe Research began coverage on Nyxoah in a research note on Tuesday, April 5th. They issued a “market perform” rating and a $21.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Nyxoah in a research note on Tuesday, December 21st. Finally, Piper Sandler reduced their price objective on Nyxoah from $40.00 to $30.00 in a research note on Friday, March 25th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $31.60.
Several hedge funds and other institutional investors have recently modified their holdings of NYXH. Banque Cantonale Vaudoise acquired a new position in shares of Nyxoah during the 3rd quarter valued at about $214,000. Credit Suisse AG acquired a new stake in Nyxoah in the 3rd quarter valued at approximately $221,000. Jane Street Group LLC acquired a new stake in Nyxoah in the 3rd quarter valued at approximately $228,000. Evolutionary Tree Capital Management LLC acquired a new stake in Nyxoah in the 3rd quarter valued at approximately $1,126,000. Finally, Monashee Investment Management LLC acquired a new stake in Nyxoah in the 3rd quarter valued at approximately $1,719,000. 10.75% of the stock is currently owned by institutional investors and hedge funds.
Nyxoah Company Profile (Get Rating)
Nyxoah SA, a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea.
- Get a free copy of the StockNews.com research report on Nyxoah (NYXH)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.